Fixed dose long-acting bronchodilator combinations in chronic obstructive pulmonary disease: safety, effectiveness and cardiovascular system

Fixed dose long-acting bronchodilator combinations in chronic obstructive pulmonary disease: safety, effectiveness and cardiovascular system

At present time, long-acting bronchodilators are the main class of drugs for basis therapy of chronic obstructive pulmonary disease (COPD). COPD is characterized not only by a decrease in pulmonary function parameters, but also by a decline in cardiac contractility. The article presents the results...

Full description

Bibliographic Details
Main Author:	I. V. Leshchenko
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2018-10-01
Series:	Медицинский совет
Subjects:	long-acting bronchodilators cardiovascular system safety efficiency
Online Access:	https://www.med-sovet.pro/jour/article/view/2667

Similar Items

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
by: Bishwakarma R, et al.
Published: (2017-01-01)

Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study
by: Yen-Fu Chen, et al.
Published: (2019-12-01)

Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis
by: Ian Naya, et al.
Published: (2019-03-01)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
by: Donohue JF, et al.
Published: (2019-12-01)

Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials
by: Li CX, et al.
Published: (2019-04-01)

Striving for optimal bronchodilation: focus on olodaterol
by: Incorvaia C, et al.
Published: (2016-03-01)

Long-Acting Bronchodilator Use in Chronic Obstructive Pulmonary Disease in Primary Care in New Zealand: A Retrospective Study of Treatment Patterns and Evolution Using the HealthStat Database
by: Milea D, et al.
Published: (2021-04-01)

Predictors of Single Bronchodilation Treatment Response for COPD: An Observational Study with the Trace Database Cohort
by: Laura Carrasco Hernández, et al.
Published: (2021-04-01)

Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review
by: Zoe A. Kopsaftis, et al.
Published: (2018-11-01)

Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
by: Pascoe S, et al.
Published: (2016-08-01)

Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD
by: Hanania NA, et al.
Published: (2018-12-01)

Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
by: Tashkin DP
Published: (2020-11-01)

Experience of using double bronchodilation therapy in patients with COPD
by: I. V. Demko, et al.
Published: (2021-01-01)

NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY
by: S. N. AVDEEV
Published: (2016-12-01)

Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline
by: Jeong HJ, et al.
Published: (2016-11-01)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
by: Tashkin DP, et al.
Published: (2018-06-01)

Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long-acting β2-agonists/long-acting muscarinic antagonists
by: Nevin Kishore, et al.
Published: (2020-01-01)

Comparison of Two Aerosolized Bronchodilators in the Treatment of Severe Equine Chronic Obstructive Pulmonary Disease
by: Friday, Philippa Anne
Published: (2011)

Small airway bronchodilator response to different doses of salbutamol in 7-year-old children
by: Dong Keon Yon, et al.
Published: (2017-08-01)

Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials
by: Jinping Zheng, et al.
Published: (2020-03-01)

BRONCHODILATOR AND TOCOLYTIC FEATURES OF β<sub>2</sub>-ADRENOCEPTOR AGONISTS
by: S. Ya. Skachilova, et al.
Published: (2019-01-01)

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
by: Beier J, et al.
Published: (2017-06-01)

Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis
by: Fabiano Di Marco, et al.
Published: (2018-01-01)

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review
by: Lopez-Campos JL, et al.
Published: (2017-06-01)

When is dual bronchodilation indicated in COPD?
by: Thomas M, et al.
Published: (2017-08-01)

Stable Clinical Course of Chronic Obstructive Pulmonary Disease Patients in the Era of Double Bronchodilator Therapy: A Single Referral Center Experience
by: Sun Hye Shin, et al.
Published: (2020-08-01)

The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study
by: Hsieh MJ, et al.
Published: (2018-09-01)

Spirometric Indices after Bronchodilator Test in Obstructive Lung Disease
by: Amir Houshang Mehrparvar, et al.
Published: (2010-07-01)

Spirometric Indices after Bronchodilator Test in Obstructive Lung Disease
by: Amir Houshang Mehrparvar, et al.
Published: (2010-08-01)

Which bronchodilator reversibility criteria can predict severe acute exacerbation in chronic obstructive pulmonary disease patients?
by: Junghyun Kim, et al.
Published: (2017-05-01)

Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD
by: Reisner C, et al.
Published: (2018-06-01)

The concept of chronic obstructive pulmonary disease clinical control as a decision - making tool in real clinical practice for optimizing of basic pharmacotherapy
by: S N Avdeev, et al.
Published: (2020-01-01)

Bronchodilator treatment of stable COPD: long-acting anticholinergics
by: W. Vincken
Published: (2005-09-01)

New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease
by: S N Avdeev, et al.
Published: (2019-03-01)

Comparison of three methods of administering a self propelled bronchodilator
by: Thompson, Anne (Anne Marie)
Published: (1980)

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology
by: D'Urzo AD, et al.
Published: (2018-09-01)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
by: Kang J, et al.
Published: (2017-12-01)

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
by: Dave Singh, et al.
Published: (2020-09-01)

Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment
by: Shih-Lung Cheng
Published: (2021-06-01)

Polymorphism of microsomal epoxide hydrolase is associated with chronic obstructive pulmonary disease and bronchodilator response
by: Chiung-Zuei Chen, et al.
Published: (2011-11-01)

Cannot write session to /tmp/vufind_sessions/sess_55j3pr6p2e6u3sihtetc945qs3